Investor and Medicinal Cannabis Update
Filed with ASX · · 14 pages · English
GMP* Manufactured (Medicinal) Cannabis products are mandatory for entry into highly regulated markets; and are emerging as a key market opportunity to convert lower value biomass into higher value differentiated products Cannabis biomass (dry flower material) is becoming commoditised as crop volumes increase and exert downward pressure on prices The global cannabis industry is expanding into more
Story so far
Earlier from IDT Australia
- FDA lifts Warning Letter
- STRATEGIC UPDATE - Medicinal Cannabis Manufacturing
- FDA revises IDTs Facility Inspection Classification
- ODC medicinal cannabis manufacturing permit secured
- IDT secures Medicinal Cannabis manufacturing license
Later from IDT Australia
- Australian produced medicinal cannabis product
- Termination of Distribution Agreement
- Commercial-Scale GMP Medicinal Cannabis Resin Extraction
- Appendix 4D
- Half Year Results Presentation
Follow IDT Australia into a list and get an email when it puts out news.
Follow IDT Australia